Multiple ascending dose study of NBI-640756 for the treatment of essential tremor.

Trial Profile

Multiple ascending dose study of NBI-640756 for the treatment of essential tremor.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs NBI 640756 (Primary)
  • Indications Essential tremor
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 14 Feb 2017 According to Neuroendocrine Biosciences media release, data from this study is expected later in 2017.
    • 03 Aug 2016 According to Neuroendocrine Biosciences media release, the results from this study are expected later in 2016.
    • 03 Aug 2016 According to Neuroendocrine Biosciences media release, planned number of patients changed to 30.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top